We use cookies to ensure that we give you the best tailored experience on our website based on your preferences. You can read more about our cookie policy here

Dr Barbara Domayne-Hayman

Industry Advisory Board Member

Chief Business Officer, Autifony Therapeutics

Dr Barbara Domayne-Hayman has a broad range of commercial, fund-raising and general management experience, with many years of business development. She is currently ‘Entrepreneur-in-residence’ at the Stevenage Bioscience Catalyst and Chief Business Officer at Autifony Therapeutics.

Previously, Barbara was CEO of Stabilitech, a platform technology company stabilising vaccinesand other biologics, for four and a half years. She raised funding, including considerable amounts from non-dilutive sources such as the US Department of Defense as well as the UK’s Technology Strategy Board, established multiple commercial collaborations and built the team from very early stage. Prior to this, she was Commercial Director at Arrow Therapeutics, an antiviral drug discovery and development company, for over four years, until the company was acquired by AstraZeneca in 2007. Before working at Arrow, Barbara was Senior Business Development Manager at Celltech. She previously held senior international commercial positions at Zeneca where she worked for over ten years. She has also consulted in Life Sciences for Ernst & Young Strategy Group, and holds a Sloan Fellowship from London Business School. She has a BA and D.Phil in chemistry, from the University of Oxford.

Other team Members

Dr Marek Tyl

CEO, Innovation Forum

View profile

Will West

View profile

Neil Burns

View profile

Lindsey Brown

Head of Content

View profile

Dr Daniel Moreno

Global Head of Marketing and Communication

View profile